Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

SAB Biotherapeutics Inc

SABS ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$3.50

▲ +3.24%

Market Cap $318.45M · Vol 77.88K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$318.45M

Small Cap

Div Yield

N/A

EPS Growth

-582.35%

YoY

RSI (14)

24.71

Momentum

Beta

0.58

vs Market

52W High

$5.15

34.17% below

52W Low

$1.85

83.24% above

Volume

77.88K

Avg 81.51K

P/B

1.18

Price-to-book

ROE

N/A

Return on equity

Free Float

92.01%

Public shares

Shariah Compliance8 STANDARDS

✗ SAB Biotherapeutics Inc (SABS) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SABS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+2.34%

-7.16%

-9.33%

-14.00%

YTD

-6.42%

+35.66%

-46.15%

-96.51%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$13.27M
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	12.23% · 14.76%

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.18
P/FCF	N/A
EPS Growth	-582.35%
Outstanding Shares	90.99M

Technical Indicators

50-Day SMA	$3.67
200-Day SMA	$3.80
RSI (14)	24.71
Beta	0.58
52-Week High	$5.15
52-Week Low	$1.85

Volume Today	77.88K
Avg Daily Volume (30D)	81.51K
Relative Volume	0.96x
Volatility (10D)	30.65
Volatility (30D)	34.61
Free Float	92.01%

Analyst Consensus

BUY

Current Price $3.50

Mean Target $11.64

52W Low$1.85 52W High$5.15

Current

Target

$1.85 $5.15

Current Analyst target

+232.47% upside potential · 11 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00YHY0GX0

ISINUS78397T2024

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +1.49% ARGX.BR argenx SE +2.29% ARGX argenx SE +1.13% INSM Insmed Incorporated +1.14% 2269.HK WuXi Biologics (Cayman) Inc. +0.32%

Company Profile

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.